Celldex Therapeutics Inc CLDX:NASDAQ

Last Price$22.70NASDAQ Previous Close - Last Trade as of 4:00PM ET 7/01/22

Today's Change-4.26(15.80%)
Bid (Size)$22.02 (1)
Ask (Size)$22.70 (2)
Day Low / High$21.65 - 24.18
Volume4.4 M
 

View Medical Specialties IndustryPeer Comparison as of 07/01/2022

 

Celldex Therapeutics Inc ( NASDAQ )

Price: $22.70
Change: -4.26 (15.80%)
Volume: 4.4 M
4:00PM ET 7/01/2022
 
 

Mesa Laboratories Inc ( NASDAQ )

Price: $206.87
Change: +2.93 (1.44%)
Volume: 29.3 K
4:00PM ET 7/01/2022
 
 

LeMaitre Vascular Inc ( NASDAQ )

Price: $46.40
Change: +0.85 (1.87%)
Volume: 74.4 K
4:00PM ET 7/01/2022
 
 

Natus Medical Inc ( NASDAQ )

Price: $32.70
Change: -0.07 (0.21%)
Volume: 183.3 K
4:00PM ET 7/01/2022
 
 

Atrion Corp ( NASDAQ )

Price: $635.68
Change: +6.82 (1.08%)
Volume: 3.8 K
4:00PM ET 7/01/2022
 

Read more news Recent News

Update: Celldex Therapeutics Shares Decline After Company Reports Interim Data From Clinical Trial of Hives Therapy
10:25AM ET 7/01/2022 MT Newswires

(Updates with share price movement in the headline, and first and second paragraphs.) Celldex Therapeutics' (CLDX) shares declined Friday morning, a day...

HC Wainwright Adjusts Celldex Therapeutics' Price Target to $73 from $60, Keeps Buy Rating
9:47AM ET 7/01/2022 MT Newswires

Celldex Therapeutics (CLDX) has an average rating of buy and price targets ranging from $59 to $68, according to analysts polled by Capital IQ. (MT...

Sector Update: Health Care Stocks Mixed Premarket Friday
9:14AM ET 7/01/2022 MT Newswires

Health care stocks were mixed premarket Friday. The Health Care SPDR (XLV) was 0.28% lower, and the iShares NASDAQ Biotechnology Index (IBB) was recently...

Celldex Therapeutics Says Early Trial Data Support Positive Effects of Hives Therapy
6:58AM ET 7/01/2022 MT Newswires

Celldex Therapeutics (CLDX) said Thursday that its candidate therapy for moderate to severe chronic spontaneous urticaria (CSU), barzolvolimab, showed...

Company Profile

Business DescriptionCelldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ. View company web site for more details
AddressPerryville III Building
Hampton, New Jersey 08827
Phone+1.908.200.7500
Number of Employees137
Recent SEC Filing06/23/20228-K
President, Chief Executive Officer & DirectorAnthony S. Marucci
CFO, Secretary, Treasurer & Senior Vice PresidentSam Martin
Chief Scientific Officer & Executive VPTibor Keler
Chief Medical Officer & Senior Vice PresidentDiane C. Young

Company Highlights

Price Open$23.56
Previous Close$26.96
52 Week Range$19.85 - 57.20
Market Capitalization$1.1 B
Shares Outstanding46.8 M
SectorHealth Technology
IndustryMedical Specialties
Next Earnings Announcement08/04/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.69
Beta vs. S&P 500N/A
Revenue$9.5 M
Net Profit Margin-1,860.01%
Return on Equity-21.45%

Analyst Ratings as of 09/16/2021

Buy
6
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset